Status:
TERMINATED
Moxonidine in Patients Undergoing Vascular Surgery
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Cardiac Disease
Vascular Surgery
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion, patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day before surgery u...
Eligibility Criteria
Inclusion
- abdominal aortic or peripheral vascular surgery
Exclusion
- unstable angina,
- severe symptomatic heart failure (NYHA IV)
- systolic blood pressure at rest \< 100 mmHg
- bradycardia (\<50/min)
- higher grade AV heart block
- creatinine clearance \< 30 ml/min
- pregnancy
- no consent
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT00244504
Start Date
November 1 2002
End Date
March 1 2006
Last Update
November 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital
Basel, CH, Switzerland, 4000